Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00541281 | Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer | PHASE2 | COMPLETED | 150 | — | — | Dec 1, 2003 | Feb 1, 2006 | Oct 27, 2009 | 19 | Belgium, Luxembourg |
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | weekly docetaxel and prednisone |
| B | ACTIVE_COMPARATOR | weekly docetaxel (35mg/m\&) plus prednisone 10mg a day associated with estramustine form day 1to 5 and 8 to 12 |
| Name | Type | Description |
|---|---|---|
| docetaxel | DRUG | 35mg/m² on day 2 and 9 (21days in a cycle) |
| estramustine | DRUG | 140mg caps x3 bid from day 1to 5 and day 8 to 12 of each cycle |
| prednisone | DRUG | 2x5 mg a day |
Inclusion Criteria: * Signed informed consent prior to beginning protocol specific procedures. * 18 years * Histologically/cytologically proven prostate adenocarcinoma. * Documented metastatic prostate adenocarcinoma * Patients must have received prior hormonal therapy as defined below: * Castratio...